JP6824876B2 - アミジン誘導体組成物及びそれらの使用 - Google Patents

アミジン誘導体組成物及びそれらの使用 Download PDF

Info

Publication number
JP6824876B2
JP6824876B2 JP2017510576A JP2017510576A JP6824876B2 JP 6824876 B2 JP6824876 B2 JP 6824876B2 JP 2017510576 A JP2017510576 A JP 2017510576A JP 2017510576 A JP2017510576 A JP 2017510576A JP 6824876 B2 JP6824876 B2 JP 6824876B2
Authority
JP
Japan
Prior art keywords
present
vitamin
pharmaceutically acceptable
poly
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017510576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525718A (ja
JP2017525718A5 (enExample
Inventor
バブー，ヤーラガッダ・エス
カマス，ビベカーナンド・ピー
ゴーワン，ウォルター
Original Assignee
バイオクライスト ファーマシューティカルズ， インコーポレイテッド
バイオクライスト ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオクライスト ファーマシューティカルズ， インコーポレイテッド, バイオクライスト ファーマシューティカルズ， インコーポレイテッド filed Critical バイオクライスト ファーマシューティカルズ， インコーポレイテッド
Publication of JP2017525718A publication Critical patent/JP2017525718A/ja
Publication of JP2017525718A5 publication Critical patent/JP2017525718A5/ja
Application granted granted Critical
Publication of JP6824876B2 publication Critical patent/JP6824876B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Treating Waste Gases (AREA)
JP2017510576A 2014-08-22 2015-08-24 アミジン誘導体組成物及びそれらの使用 Active JP6824876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040836P 2014-08-22 2014-08-22
US62/040,836 2014-08-22
PCT/US2015/046578 WO2016029214A1 (en) 2014-08-22 2015-08-24 Compositions and uses of amidine derivatives

Publications (3)

Publication Number Publication Date
JP2017525718A JP2017525718A (ja) 2017-09-07
JP2017525718A5 JP2017525718A5 (enExample) 2018-09-27
JP6824876B2 true JP6824876B2 (ja) 2021-02-03

Family

ID=54012341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017510576A Active JP6824876B2 (ja) 2014-08-22 2015-08-24 アミジン誘導体組成物及びそれらの使用

Country Status (8)

Country Link
US (1) US10905683B2 (enExample)
EP (1) EP3182962B1 (enExample)
JP (1) JP6824876B2 (enExample)
AU (1) AU2015305214B2 (enExample)
CA (1) CA2959026C (enExample)
DK (1) DK3182962T3 (enExample)
ES (1) ES2954451T3 (enExample)
WO (1) WO2016029214A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
HUE049918T2 (hu) 2016-05-31 2020-11-30 Kalvista Pharmaceuticals Ltd Pirazol-származékok mint plazma kallikrein inhibitorok
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106565442B (zh) * 2016-08-24 2019-07-16 浙江美诺华药物化学有限公司 3-(3-氟苄基)-4-(3-氟苄氧基)苯甲醛的制备方法
CN106632223B (zh) * 2016-08-24 2019-04-23 浙江美诺华药物化学有限公司 2-(3-溴-4-(3-氟苄氧基)苯基)-1,3-二氧戊环及其制备方法
US10759759B2 (en) 2016-10-31 2020-09-01 Biocryst Pharmaceuticals, Inc. Prodrugs of kallikrein inhibitors
CN106977382A (zh) * 2017-04-28 2017-07-25 山东新华制药股份有限公司 4‑（3‑氟苄氧基）苯甲醛的制备方法
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
SI3716952T1 (sl) 2017-11-29 2022-04-29 Kalvista Pharmaceuticals Limited Farmacevtske oblike, ki obsegajo zaviralec plazemskega kalikreina
AU2020273154A1 (en) * 2019-04-08 2021-12-02 Biocryst Pharmaceuticals, Inc. Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
WO2022006232A2 (en) * 2020-07-01 2022-01-06 The Board Of Trustees Of The Leland Stanford Junior University Drug repurposing for treatment of viral infections
AU2021427558A1 (en) * 2021-02-09 2023-08-31 Phebra Pty Ltd Method of preparing a topical pharmaceutical composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1540979A (en) 1923-04-11 1925-06-09 Swift & Co Machine for testing jelly strength of glues, gelatins, and the like
CA2426430C (en) 2000-10-20 2014-10-07 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors
RU2003132706A (ru) * 2001-04-06 2005-04-20 Байокрист Фармасьютикалз, Инк. (Us) Диариловые соединения в качестве ингибиторов сериновых протеаз
CA3061802C (en) * 2011-09-08 2022-04-05 Intrexon Corporation Crystalline diacylhydrazine and the use thereof
WO2014057069A1 (en) 2012-10-10 2014-04-17 Novo Nordisk Health Care Ag Liquid pharmaceutical composition of factor vii polypeptide

Also Published As

Publication number Publication date
US20170266172A1 (en) 2017-09-21
JP2017525718A (ja) 2017-09-07
CA2959026A1 (en) 2016-02-25
WO2016029214A1 (en) 2016-02-25
ES2954451T3 (es) 2023-11-22
DK3182962T3 (da) 2023-09-18
EP3182962A1 (en) 2017-06-28
AU2015305214A1 (en) 2017-03-16
US10905683B2 (en) 2021-02-02
EP3182962B1 (en) 2023-06-07
WO2016029214A9 (en) 2017-01-05
AU2015305214B2 (en) 2020-04-23
CA2959026C (en) 2023-10-24

Similar Documents

Publication Publication Date Title
JP6824876B2 (ja) アミジン誘導体組成物及びそれらの使用
JP7656589B2 (ja) エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
JP7641320B2 (ja) ｓＧＣ刺激薬を含んでなる固体分散剤
JP2019537585A (ja) Ｅｚｈ２媒介性がんを治療するための組成物および方法
JP2013079234A (ja) Ｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミドの医薬組成物
JP2021522247A (ja) 肝疾患における好中球エラスターゼ阻害薬の使用
KR20230015934A (ko) 전립선암 치료 방법
US9402850B2 (en) BAX agonist, compositions, and methods related thereto
US20230141981A1 (en) Novel compounds and composition for targeted therapy of kidney-associated cancers
Roy et al. Design and synthesis of orally active Quinolyl Pyrazinamides as sigma 2 receptor ligands for the treatment of pancreatic cancer
WO2007111720A2 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
TW201338777A (zh) 用於治療金屬過載之經口調配物
CN1092645C (zh) 糖尿病并发症的预防/治疗药
JP2016532659A (ja) イコチニブ含有皮膚外用医薬組成物及びその応用
WO2014013465A2 (en) Salts and hydrates of antipsychotics
EA032865B1 (ru) НОВАЯ КРИСТАЛЛИЧЕСКАЯ СОЛЕВАЯ ФОРМА 3-(1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИН-3-ИЛЭТИНИЛ)-4-МЕТИЛ-N-(4-((4-МЕТИЛПИПЕРАЗИН-1-ИЛ)МЕТИЛ)-3-ТРИФТОРМЕТИЛФЕНИЛ)БЕНЗАМИДА ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ
HK1239546A1 (en) Compositions and uses of amidine derivatives
HK1239546B (en) Compositions and uses of amidine derivatives
US20240376155A1 (en) Novel compounds and compositions for targeted therapy of renal cancers
AU2018373028A1 (en) Polymorphs and uses thereof
TW202140004A (zh) 用於治療ｎａｆｌｄ／ｎａｓｈ及相關疾病之組合
TW202448441A (zh) 脯氨醯羥化酶抑制劑及其用途
CN115298159A (zh) 与氧化应激相关的病症的治疗和用于其的化合物
WO2017035263A1 (en) Compositions comprising a plasma kallikrein inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210113

R150 Certificate of patent or registration of utility model

Ref document number: 6824876

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250